Urology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Holcomb IN et al. – Androgen deprivation is the mainstay of therapy for progressive prostate cancer. Despite initial and dramatic tumor inhibition, most men eventually fail therapy and die of metastatic castration–resistant (CR) disease. The authors find the fusion in 54% of the CR tumors, and 81% of the fusion–positive tumors contain cells with multiple copies of the fusion. The investigation lays the foundation for a better understanding of and possible therapeutic targets for CR disease, the poorly responsive and final stage of prostate cancer.

Related Articles

Risk of dying from prostate cancer in men randomized to screening
Cancer, 10/13/09    Relevance Score: 72%

Validation in a Multiple Urology Practice Cohort of the Prostate Cancer Prevention Trial Calculator for Predicting Prostate Cancer Detection
The Journal of Urology, 11/13/09    Relevance Score: 71%

A prospective study of lifetime physical activity and prostate cancer incidence and mortality
British Journal of Cancer, 11/02/09    Relevance Score: 71%

Association of 17 prostate cancer susceptibility loci with prostate cancer risk in Chinese men
The Prostate, 11/02/09    Relevance Score: 71%

Prostate specific antigen for early detection of prostate cancer: longitudinal study
British Medical Journal, 10/08/09    Relevance Score: 71%

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address